Physician profile
Elissa B Gartenberg
NPI 1639152291
$2,868.53
in general payments reported to CMS, 2019-2025
28 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $446 · 2021: $759 · 2022: $407 · 2023: $384 · 2024: $126 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $656.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $464.88 | 2019-2023 | |
| Lilly USA, LLC | $385.21 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Lucid Diagnostics INC. | $258.45 | 2021-2023 | |
| Allergan, INC. | $242.48 | 2019-2020 | |
| Amgen INC. | $192.72 | 2021-2025 | Evenity, Prolia, Repatha |
| Teva Pharmaceuticals USA, INC. | $106.13 | 2020 | |
| Therapeuticsmd, INC. | $92.75 | 2019 | |
| Alfasigma USA, INC. | $77.13 | 2020-2021 | |
| Hologic Sales and Service, LLC | $38.76 | 2019-2024 | Thinprep 2000 Processor, Aptima |
| Exact Sciences Corporation | $33.66 | 2023-2025 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $28.41 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.30 | 2024 | |
| Abiomed | $26.47 | 2023 | Impella |
| Axonics, INC. | $23.88 | 2023 | Axonics |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.33 | 2022 | |
| Zoll Respicardia, INC. | $20.59 | 2024 | Remede System |
| Redhill Biopharma INC. | $18.73 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $17.72 | 2023 | Farxiga |
| Teleflex LLC | $16.69 | 2023 | Urolift |
| Impel Pharmaceuticals LLC | $16.64 | 2025 | Trudhesa |
| Alnylam Pharmaceuticals INC. | $16.26 | 2023 | Givlaari |
| Bardy Diagnostics, INC. | $15.86 | 2021 | |
| Galderma Laboratories, L.P. | $15.38 | 2025 | |
| Cranial Technologies, INC | $14.60 | 2024 | Doc Band |
| Acella Pharmaceuticals, LLC | $13.64 | 2025 | NP Thyroid 60 |
| Biohaven Pharmaceuticals, INC. | $12.19 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elissa Gartenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.